Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide in Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma
NCT00413036Phase 2Completed
- Sponsor
- Celgene Corporation
- Start
- Jun 2006
- Primary completion
- Apr 2011
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 2, open-label, single-arm trial of lenalidomide in Non-Hodgkin lymphoma (NHL), sponsored by Celgene Corporation. Primary endpoint: Participants Categorized by Best Response as Determined by Central Review up to 1459 days. Started Jun 2006; status: completed.
02
Drugs
lenalidomide
03
Conditions
Non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT00413036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00413036.